Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Renalytix's share price for the quarter that ended in Dec. 2025 was $3.62. Renalytix's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 8.74 Mil. Therefore, Renalytix's market cap for the quarter that ended in Dec. 2025 was $31.64 Mil.
Renalytix's quarterly market cap
declined
from Dec. 2024 ($34.78 Mil) to Jun. 2025 ($30.64 Mil) but then
increased
from Jun. 2025 ($30.64 Mil) to Dec. 2025 ($31.64 Mil).
Renalytix's annual market cap
declined
from Jun. 2023 ($136.95 Mil) to Jun. 2024 ($17.83 Mil) but then
increased
from Jun. 2024 ($17.83 Mil) to Jun. 2025 ($30.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Renalytix's Enterprise Value for Today is $12.87 Mil.
Renalytix (OTCPK:RNLXD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Renalytix Market Cap Related Terms
Renalytix Market Cap Historical Data
* Premium members only.
The historical data trend for Renalytix's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Renalytix's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renalytix Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Market Cap distribution charts can be found below:
* The bar in red indicates where Renalytix's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Renalytix's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renalytix (RNLXD) has a Market Cap of $13.27 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #553 out of 695 companies in the Healthcare Providers & Services industry, placing it in the top 79.6%.
Is Renalytix's Market Cap too high?
Renalytix's current Market Cap is $13.27 Mil. The Healthcare Providers & Services industry median Market Cap is 95.72. Renalytix's value of $13.27 Mil is 86.1% below this industry median. Based on the distribution chart, Renalytix ranks #553 out of 695 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Renalytix has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Market Cap compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #553 out of 695 companies for Market Cap. This places Renalytix in the lower half of its industry. The industry median Market Cap is 95.72. Renalytix's value of $13.27 Mil is 86.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 95.72, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renalytix's current Market Cap of $13.27 Mil is 86.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 95.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current Market Cap is $13.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (RNLXD) has a current Market Cap of $13.27 Mil. The stock's GF Value™ is $10.82, compared to a current price of $4.11 — trading 62% below its estimated fair value. The current Market Cap is $13.27 Mil and 86.1% below the Healthcare Providers & Services industry median of 95.72. Renalytix's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Renalytix (RNLXD), the current Market Cap is $13.27 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renalytix (RNLXD) Overvalued in 2026?
Based on GuruFocus' analysis, Renalytix stock appears to be undervalued.
The current stock price of $4.11 is trading 62% below its estimated GF Value™ of $10.82.
Key valuation signals for RNLXD:
Market Cap: $13.27 Mil
GF Value™: $10.82 vs. price of $4.11 (62% below fair value)
Industry Position: 86.1% below the Healthcare Providers & Services median (#553 of 695)
No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score
Get the complete analysis for RNLXD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNLXD has been successfully added to your 
